Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Open access
Hong, David S., Van Tine, Brian A., Biswas, Swethajit, McAlpine, Cheryl, Johnson, Melissa L., Olszanski, Anthony J., Clarke, Jeffrey M., Araujo, Dejka, Blumenschein, George R., Kebriaei, Partow, Lin, Quan, Tipping, Alex J., Sanderson, Joseph P., Wang, Ruoxi, Trivedi, Trupti, Annareddy, Thejo, Bai, Jane, Rafail, Stavros, Sun, Amy, Fernandes, Lilliam, Navenot, Jean-Marc, Bushman, Frederic D., Everett, John K., Karadeniz, Derin, Broad, Robyn, Isabelle, Martin, Naidoo, Revashnee, Bath, Natalie, Betts, Gareth, Wolchinsky, Zohar, Batrakou, Dzmitry G., Van Winkle, Erin, Elefant, Erica, Ghobadi, Armin, Cashen, Amanda, Grand’Maison, Anne, McCarthy, Philip, Fracasso, Paula M., Norry, Elliot, Williams, Dennis, Druta, Mihaela, Liebner, David A., Odunsi, Kunle, Butler, Marcus O. · 2023 · Nature Medicine

Abstract

Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in multiple solid tumors. We conducted a multicenter, dose-escalation, phase 1 trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma (SS), ovarian cancer and head and neck cancer (NCT03132922). The primary endpoint was safety, and the secondary efficacy endpoints included overall response rate (ORR) and duration of response. All patients (N = 38, nine tumor types) experienced Grade ≥3 hematologic toxicities; 55% of patients (90% Grade ≤2) experienced cytokine release syndrome. ORR (all partial response) was 24% (9/38), 7/16 (44%) for SS and 2/22 (9%) for all other cancers. Median duration of response was 25.6 weeks (95% confidence interval (CI): 12.286, not reached) and 28.1 weeks (95% CI: 12.286, not reached) overall and for SS, respectively. Exploratory analyses showed that afami-cel infiltrates tumors, has an interferon-γ-driven mechanism of action and triggers adaptive immune responses. In addition, afami-cel has an acceptable benefit–risk profile, with early and durable responses, especially in patients with metastatic SS. Although the small trial size limits conclusions that can be drawn, the results warrant further testing in larger studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02128-z

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 203

Metadata

Authors
Hong, D. S., Van Tine, B. A., Biswas, S., McAlpine, C., Johnson, M. L., Olszanski, A. J., Clarke, J. M., Araujo, D., Blumenschein, G. R., Kebriaei, P., Lin, Q., Tipping, A. J., Sanderson, J. P., Wang, R., Trivedi, T., Annareddy, T., Bai, J., Rafail, S., Sun, A., Fernandes, L., Navenot, J.-M., Bushman, F. D., Everett, J. K., Karadeniz, D., Broad, R., Isabelle, M., Naidoo, R., Bath, N., Betts, G., Wolchinsky, Z., Batrakou, D. G., Van Winkle, E., Elefant, E., Ghobadi, A., Cashen, A., Grand’Maison, A., McCarthy, P., Fracasso, P. M., Norry, E., Williams, D., Druta, M., Liebner, D. A., Odunsi, K., & Butler, M. O.
Venue
Nature Medicine
Published
2023-01
Volume
29
Issue
1
Pages
104-114
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4313893438
Cited by
203
References
6
FWCI
21.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-022-02128-z
The paper
Hong, D. S., Van Tine, B. A., Biswas, S., McAlpine, C., Johnson, M. L., Olszanski, A. J., Clarke, J. M., Araujo, D., Blumenschein, G. R., Kebriaei, P., Lin, Q., Tipping, A. J., Sanderson, J. P., Wang, R., Trivedi, T., Annareddy, T., Bai, J., Rafail, S., Sun, A., . . . Butler, M. O. (2023). Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-022-02128-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.